ÕÒÂÛÎÄÍø > ҽҩѧÂÛÎÄ > ҩѧÂÛÎÄ >

¸´·½»Ç°·¼×¿Ú¶ñßòÓëÌæ¿¨Î÷ÁÖ/¿ËÀ­Î¬Ëᡢͷæßßßͪ/Êæ°Í̹ÁªÓöÔÊÈÂóÑ¿¹ÑÑøµ¥°û¾úÌåÍ⿹¾ú»îÐÔµÄÑо¿(1)

¡¾ÕªÒª¡¿  Ä¿µÄ ÆÀ¼Û¸´·½»Ç°·¼×¿Ú¶ñßò·Ö±ðÓëÌæ¿¨Î÷ÁÖ/¿ËÀ­Î¬Ëᡢͷæßßßͪ/Êæ°Í̹Á½Ö֦ª²ÄÚõ£°·Ã¸ÒÖÖÆ¼ÁÁªºÏÓ¦ÓöÔÓÚÁÙ´²·ÖÀë30ÖêÊÈÂóÑ¿¹ÑÑøµ¥°û¾úµÄÌåÍâÁªºÏ¿¹¾úЧӦ¡£·½·¨ ²ÉÓÃÆåÅÌ·¨Éè¼Æ£¬Î¢Á¿ÈâÌÀÏ¡ÊÍ·¨²â¶¨²»Í¬Å¨¶È×éºÏµÄ2×鿹¾úÒ©Îï¶Ô30ÖêÊÈÂóÑ¿¹ÑÑøµ¥°û¾úµÄ×îµÍÒÖ¾úŨ¶È£¬²¢¼ÆËãÁªºÏÒÖ¾úÖ¸Êý(FIC)£¬ÅжÏÁªºÏЧӦ¡£½á¹û ¸´·½»Ç°·¼×¿Ú¶ñßò¶ÔÊÈÂóÑ¿¹ÑÑøµ¥°û¾úµÄMICΪ2/38£¬ÓëÌæ¿¨Î÷ÁÖ/¿ËÀ­Î¬Ëᡢͷæßßßͪ/Êæ°Í̹ÁªºÏÓ¦ÓÃºó£¬ÆäMIC50ÏÔÖø½µµÍÖÁ0.5/9.5£¬FICÖ¸Êý·Ö²¼·¶Î§Ö÷ÒªÔÚ0¡«1¡£½áÂÛ ¸´·½»Ç°·¼×¿Ú¶ñßòÓëÌæ¿¨Î÷ÁÖ/¿ËÀ­Î¬Ëᡢͷæßßßͪ/Êæ°Í̹Á½Ö֦ª²ÄÚõ£°·/øÒÖÖÆ¼ÁÁªºÏÓ¦Óú󣬶ÔÊÈÂóÑ¿¹ÑÑøµ¥°û¾ú±íÏÖΪЭͬ×÷ÓúÍÏà¼Ó×÷Ó㬲¢ÒÔЭͬ×÷ÓÃΪÖ÷¡£

¡¾¹Ø¼ü´Ê¡¿  ÊÈÂóÑ¿¹ÑÑøµ¥°û¾ú ¸´·½»Ç°·¼×¿Ú¶ñßò Ìæ¿¨Î÷ÁÖ/¿ËÀ­Î¬Ëá Í·æßßßͪ/Êæ°Í̹ ÁªºÏÒ©Ãô

    In vitro antibacterial activity of compound sulfamethoxazole combined

      ABSTRACT  Objective  To evaluate the antibiotic effects of SMZ/TMP combined with TIPC/CA, CPZ/SB respectively against 30 Stenotrophomonas maltophilia.  Methods  The protocol was designed by checkerboard method and the MIC of two groups antibiotics against 30 Stenotrophomonas maltophilia was determined by dilution method and the FIC index was calculated according to MIC results.  Results  The in vitro antibacterial activity of MICs of combinations were lower than those of 3 drugs tested alone. The range of the FIC index was mainly between 0¡«1.  Conclusion  The FIC index indicated that synergism and additiª²vity of SMZ/TMP combined with TIPC/CA, CPZ/SB respectively against 30 Stenotrophomonas maltophilia.

    KEY WORDS  Stenotrophomonas maltophilia;  Compound sulfamothoxazole;  Ticarcillin/clavulanic acid;  Cefoperazone/sulbactam;  FIC

     ÊÈÂóÑ¿¹ÑÑøµ¥°û¾ú(Stenotrophomonas maltoª²philia)ÊÇÐèÑõ¡¢·Ç·¢½ÍµÄ¸ïÀ¼ÒõÐԸ˾ú£¬¸Ã¾ú¹ã·º·Ö²¼ÓÚ×ÔÈ»½ç£¬ÎªÖ÷ÒªµÄÌõ¼þÖ²¡¾úºÍÔºÄÚ¸ÐȾµÄ²¡Ô­¾úÖ®Ò»£¬¶à·¢ÉúÓÚÀÏÄêÈËÇÒ³¤ÆÚʹÓùãÆ×¿¹ÉúËØºÍ½øÐÐÇÖÈëÐÔÖÎÁÆ»¼ÕߵĺôÎüµÀ±ê±¾ÖС£´Ë¾ú¶Ô³£ÓõĿ¹ÉúËØÓнϸߵÄÄÍÒ©ÐÔ£¬ÇÒ¶ÔÑǰ·ÅàÄÏÌìÈ»ÄÍÒ©£¬ÁÙ´²ÖÎÁƷdz£À§ÄÑ£¬²¡ËÀÂʽϸߡ£¸´·½»Ç°·¼×¿Ú¶ñßò¡¢Ì濨Î÷ÁÖ/¿ËÀ­Î¬Ëᡢͷæßßßͪ/Êæ°Í̹Ãô¸ÐÐÔËäÈ»Ïà¶ÔºÃЩ£¬µ«ÆäÄÍÒ©ÐÔÈÔÔÚ20%ÒÔÉÏ£Û1£Ý£¬ÕâÈýÖÖÒ©ÎïÁÙ´²Éϵ¥¶ÀʹÓÃʱÁÆÐ§²»ÀíÏ룬¶ø²ÉÓÃÁªºÏÓÃÒ©¿ÉÌá¸ßÁÆÐ§¡£±¾ÎÄÄâ̽ÌÖ¸´·½»Ç°·¼×¿Ú¶ñßò·Ö±ðÓëÌæ¿¨Î÷ÁÖ/¿ËÀ­Î¬Ëᡢͷæßßßͪ/Êæ°Í̹ÁªºÏÓ¦ÓõÄÌåÍ⿹¾ú»îÐÔ£¬ÎªÁÙ´²ÁªºÏÓÃÒ©£¬¼õÉÙÄÍÒ©¾úÖêÌṩʵÑéÒÀ¾Ý¡£

    1  ²ÄÁϺͷ½·¨

¡¡¡¡1.1  ¾úÖê

    30ÖêÊÈÂóÑ¿¹ÑÑøµ¥°û¾úÀ´Ô´ÓÚÁÙ´²±ê±¾£¬ÆäÖÐ̵28Ö꣬µ¨Ö­ÒýÁ÷Îï2Ö꣬¾­VITEKÖØÐ¼ø¶¨È·ÈÏ¡£ÖʿؾúΪͭÂ̼ٵ¥°û¾úATCC27853¡£

    1.2  ÅàÑø»ù

    Ë®½âÀÒµ°°×(MH)ÒºÌåÅàÑø»ù(ÖйúÒ©Æ·ÉúÎïÖÆÆ·¼ì¶¨Ëù)¡£

    1.3  ¿¹¾úÒ©Îï

    ¸´·½»Ç°·¼×¿Ú¶ñßò£Û¼×ÑõÜÐडûǰ·¼×»ùÒì¿Ú¶ñßò(1¡Ã19)£Ý(Ìì½ò½ðÕ¿Ƽ¼·¢Õ¹ÓÐÏÞ¹«Ë¾ÅäÖÆ)£¬Ì濨Î÷ÁÖ/¿ËÀ­Î¬ËᣬÖÐÃÀÊ·¿Ë¹«Ë¾(ÅúºÅ166746£¬´¿¶È94%£¬º¬Ì濨Î÷ÁÖ3g£¬¿ËÀ­Î¬Ëá0.2g)£¬Í·æßßßͪ/Êæ°Í̹£¬PfizerÖÆÒ©ÓÐÏÞ¹«Ë¾(ÅúºÅ55839229£¬´¿¶È93%£¬Í·æßßßͪ/Êæ°Í̹Ϊ2¡Ã1)¡£

    1.4  ÒÇÆ÷

    ±È×ÇÒÇ(·¨¹úBioª²Merieux¹«Ë¾²úÆ·)£»Á¬ÐøÎ¢Á¿¼ÓÑùÆ÷ºÍ°ËµÀ΢Á¿¼ÓÑùÆ÷¾ùΪÃÀ¹úEppendorf¹«Ë¾²úÆ·)£»96¿×ƽ°å(Ìì½ò½ðÕ¿Ƽ¼·¢Õ¹ÓÐÏÞ¹«Ë¾)¡£

    2  ·½·¨ºÍ½á¹û

    2.1  ¾úÐüÒºÅäÖÆ

    ´ÓÒÑ·Ö´¿²¢¹ýÒ¹ÐÂÏÊÅàÑøµÄϸ¾úƽ°åÉÏÌôÈ¡4¡«5¸ö¾úÂ䣬½ÓÖÖÓÚMHÈâÌÀÖÐÔö¾ú6h£¬¾úÒºÓÃ3mlÈâÌÀÒÔ±È×ÇÒÇУÕý×ǶÈÖÁ1.5¡Á108CFU/ml£¬ÔÙÒÔMHÈâÌÀÏ¡ÊÍÖÁ1.5¡Á105CFU/ml¡£

    2.2  ¿¹¾úÒ©Îï´¢±¸ÒºÅäÖÆ

    Ìæ¿¨Î÷ÁÖ/¿ËÀ­Î¬Ëᡢͷæßßßͪ/Êæ°Í̹ÓÃpH6.0µÄPBS»º³åÒºÅä³É×îÖÕŨ¶ÈΪ1920¦Ìg/mlµÄ¿¹ÉúËØ´¢±¸Òº¡£

¹²2Ò³: 1 [2] ÏÂÒ»Ò³


¶¡Ï©Ëá¶Ô¼×Ñõ»ùÜÐõ¥µÄºÏ³ÉÓë±íÕ÷
»Ò»ÆÃ¹Ëس¬Éù²¨ÌáÈ¡¹¤ÒÕÑо¿
¹¤É̹ÜÀí | ¹¤¿ÆÂÛÎÄ | ²ÆÎñ¹ÜÀí | ¹ÜÀíѧ | ¹«¹²¹ÜÀí | ²ÆÕþ˰ÊÕ | ֤ȯ½ðÈÚ | »á¼ÆÉó¼Æ | ¼ÆËã»ú | ·¨ÂÉÂÛÎÄ | ҽҩѧ | ººÓïÑÔÎÄѧ
Éç»áÂÛÎÄ | ¹¤¿ÆÂÛÎÄ | Àí¿ÆÂÛÎÄ | ÎÄ»¯ÂÛÎÄ | ÒÕÊõÂÛÎÄ | ÎÄѧÂÛÎÄ | ÕÜѧÂÛÎÄ | ÕþÖÎÂÛÎÄ | Ó¢ÓïÂÛÎÄ | д×÷Ö¸µ¼ | ¼ÆËã»úÓ¦ÓÃ
www.zlunwen.com ÕÒÂÛÎÄÍø ® °æÈ¨ËùÓÐ ÍøÕ¾µØÍ¼